CAR-gamma delta T-cell

CAR-gamma delta (γδ) T-cell therapy is a form of adoptive cellular immunotherapy in which gamma-delta (γδ) T cells are genetically engineered to express a chimeric antigen receptor (CAR) targeting specific tumor antigens. Unlike conventional alpha-beta (αβ) CAR-T therapies, γδ T cells recognize and kill tumor cells in an MHC-independent manner, providing broader anti-tumor activity and potentially reducing the risk of graft-versus-host disease. These therapies can be developed as allogeneic "off-the-shelf" products from healthy donors. Preclinical and early clinical studies have shown that CAR-modified γδ T cells exhibit potent cytotoxicity against both hematological malignancies (such as B-cell lymphoma, acute myeloid leukemia) and solid tumors (such as gastric cancer expressing Claudin18.2 or prostate cancer expressing PSCA). Multiple targets have been explored, including CD20, CD33, Claudin18.2, PSCA, and CD38[3][4][5][6][7][8]. Developers include Adicet Bio for anti-CD20 γδ-CAR-Ts and IN8bio for other γδ-based immunotherapies[6][9].

Other names

CAR-gamma delta T cellγδ CAR-T cellGamma-delta chimeric antigen receptor T cell